Journal
PLASTIC AND RECONSTRUCTIVE SURGERY
Volume 127, Issue 2, Pages 580-587Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PRS.0b013e3181fed5ae
Keywords
-
Categories
Funding
- National Institutes of Health/National Institute of Dental and Craniofacial Research [R21 DE0177711-01, DE01607-01]
- United States Army U.S. Army Medical Research Acquisition Activity [07128099]
- University of California [Bio07-10677]
- Musculoskeletal Transplant Foundation [20082668]
Ask authors/readers for more resources
Background: Effective regeneration of bone is critical for fracture repair and incorporation and healing of bone grafts used during orthopedic, dental, and craniofacial reconstructions. Nel-like molecule-1 (Nell-1) is a secreted protein identified from prematurely fused cranial sutures of craniosynostosis patients that has been found to specifically stimulate osteogenic cell differentiation and bone formation. To test the in vivo osteoinductive capacity of Nell-1, a criticalsized femoral segmental defect model in athymic rats was used. Methods: A 6-mm defect, which predictably leads to nonunion if left untreated, was created in the left femur of each rat. Three treatment groups (n = 8 each) were created consisting of rats treated with (1) 1.5 mg/ml Nell-1, (2) 0.6 mg/ml Nell-1, and (3) phosphate-buffered saline only as a Nell-free control. Phosphate-buffered saline or Nell-1 was mixed with demineralized bone matrix as a carrier before implantation. All animals were euthanized 12 weeks after surgery, and bone regeneration was evaluated using radiographic, three-dimensional micro-computed tomographic, and histologic analysis. Results: Both Nell-1-treated groups had significantly greater bone formation compared with the Nell-free group, with bone volume increasing with increasing Nell-1 concentration. Conclusions: Nell-1 in a demineralized bone matrix carrier can significantly improve bone regeneration in a critical-sized femoral segmental defect in a dose-dependent manner. The results of this study demonstrate that Nell-1 is a potent osteospecific growth factor that warrants further investigation. Results also support the potential application of Nell-1 as a bone graft substitute in multiple clinical scenarios involving repair of critical bone loss when autograft bone is limited or unavailable. (Plast. Reconstr. Surg. 127: 580, 2011.)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available